Direkt zum Inhalt

ZURICH HEART HOUSE

Holiday Card

Das Zurich Heart House schafft und vermittelt neues Wissen im Bereich Herz- und Kreislauferkrankungen. Durch seine Affiliation mit der Universität Zürich, das Redaktionsmandat des «European Heart Journal» und als Sitz der «Foundation for Cardiovascular Research» gehört das Zurich Heart House zu den wichtigsten kardiologischen Forschungs- und Ausbildungszentren in Europa.

Das Zurich Heart House ist ein Ort des kreativen Wissensaustausches zwischen Forschern, Wissenschaftlern, Klinikern, niedergelassenen Ärzten, Dozenten und Mitarbeitern. Als Denkfabrik soll es den Standort Zürich stärken und als Dienstleistungszentrum Ärzten und Patienten mit Herzkreislauferkrankungen zur Verfügung stehen.

Wenn Sie über alle unsere Veranstaltungen auf dem Laufenden bleiben wollen, abonnieren Sie unseren Newsletter HIER!


Tätigkeitsbericht 2023

 


 

Applications for the PCHF London 2025 - 2026 | 4th Edition are now OPEN!

PCHFL4thEdition

 

ZHH News

Peri-Echo 2026

Postgraduate Course in Periprocedural Echocardiography 2026 | Replay videos are NOW available on demand!

The video recordings of the  Postgraduate Course in Periprocedural Echocardiography 2026 are now available on demand HERE!

Florian A. Wenzl Award

Dr. Florian A. Wenzl receives 'Breakthrough of the Year' Recognition and Hans and Blanca Moser Research Prize

For his work on applying artificial intelligence (AI) to refine cardiovascular risk prediction, Dr. Florian A. Wenzl recently received the 'Breakthrough of the Year' Recognition....

Learn more here!

CMM 2026

Postgraduate Course in Cardiometabolic Medicine 2026 | Replay videos are NOW available on demand!

The video recordings of the  Postgraduate Course in Cardiometabolic Medicine 2026 are now available on demand HERE!

Kardiologie News

Takotsubo

Takotsubo syndrome diagnosis: the biomarker-based BioTAK score

Currently, takotsubo syndrome (TTS) is diagnosed based on clinical examination, medical, psychiatric, and neurological history, repeated cardiac imaging, and coronary angiography, leading to delayed diagnosis and potentially avoidable invasive procedures. Can biomarkers help the early differentiation of TTS from acute coronary syndrome (ACS)?

Read full article (Eur Heart J. 2026;00:1–14) here!
 

Adrenomedullin

Adrenomedullin system dysregulation predicts cardiogenic shock and mortality in acute coronary syndromes

Does the inclusion of markers of the adrenomedullin (ADM) system improve early prediction of cardiogenic shock and mortality
in initially stable patients with acute coronary syndromes (ACS)?

Read the full article (Eur Heart J. 2026;00:1–16) here!

CONSORT diagram

Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial

In a first-in-human trial (NI006-101), the monoclonal antibody cliramitug, targeting misfolded transthyretin, demonstrated a favorable safety profile and time- and dose-dependent reductions in surrogate markers of cardiac amyloid burden over the course of 12 months in patients with amyloid transthyretin cardiomyopathy (ATTR-CM). 

Read full article ( Nat Med 2026 Jun 26) here!